The efficacy and tolerability of ultra-hypofractionated radiotherapy in low-intermediate risk prostate cancer patients: single center experience

Figures & data

Table 1. Patients and treatment characteristics.

Patients characteristics	Number (%) n = 44
Age	71.5 (67.25–76)
T stage
T2a	28 (63.6)
T2b	12 (27.3)
T2c	4 (9.1)
Gleason score
6 (3 + 3)	32 (72.7)
7 (3 + 4)	8 (18.2)
7 (4 + 3)	4 (9.1)
PSA level
<10	26 (59.1)
≥10	18 (40.9)
D’Amico class
Low-risk	17 (38.6)
İntermediate risk	27 (61.4)
ADT
Yes	23 (52,3)
No	21 (47.7)
RT dose
35 Gy/5 fx	18 (40.9)
36.25 Gy/5 fx	26 (59.1)
RT regimen
Daily	17 (38.6)
Every other day	27 (61.4)
Prostate volume, cc	48.6 (36–75.5)
CTV, cc	50,2 (13.8–172.2)
PTV, cc	110.25 (80.3–152.5)

PSA: prostate specific antigen; RT: radiotherapy; CTV: clinical target volume; PTV: planning target volume.

Figure 1. Kaplan-Meier survival curves. a) Overall survival, b) bRFS (biochemical recurrence-free survival).

Table 2. Toxicities by grades.

Toxicity	Grade 2	Grade 3	Grade 4
Acute GU	15 (34.1)	0	0
Acute GI	4 (9.1)	3 (6.8)	0
Late GU	3 (6.8)	2 (4.5)	0
Late GI	1 (2.3)	3 (6.8)	0

GU: genitourinary; GI: gastrointestinal.

Table 3. Comparing PSA levels and Grade ≥3 toxicities between 5 consecutive day and alternating day.

	5 consecutive	Alternating day	p value
Time of PSA
Pre-RT	9.25 (6.81–12)	8.81 (6.06–13.53)	.754
Post-RT first	0.12 (0.028–3.015)	2.37 (0.027–4.5)	.091
Post-RT 12. Months	0.081 (0.020–0.375)	1.015 (0.064–1.80)	.028
Post-RT 24. Months	0.14 (0.040–0.28)	0.17 (0.01–0.82)	.333
Nadir PSA	0.01 (0.003–0.08)	0.11 (0.008–0.8)	.013
Time to achieve nadir PSA (month)	8 (4.5–29)	24 (7.75–28.5)	.237
Grade ≥3 toxicities
Acute GI	3 (17.6%)	0	.051
Acute GU	0	0
Late GI	1 (5.9%)	2 (7.7%)	1
Late GU	2 (11.8%)	0	.151

RT: radiotherapy; PSA: prostate specific antigen; PTV: planning target volume; GU: genitourinary; GI: gastrointestinal.

Table 4. Comparing grade ≥3 toxicity between non-ADT and ADT group.

	Total (n = 44)	Non-ADT (n = 21)	ADT (n = 23)	p value
Grade ≥3 toxicity
Acute GI	3 (6.8%)	0	3 (13%)	.234
Acute GU	0	0	0	–
Late GI	3 (7%)	0	3 (13%)	.236
Late GU	2 (4.7%)	0	2 (8.7%)	.491

GI: gastrointestinal; GU: genitourinary.

Table 5. Comparing grade ≥2 toxicity between PTV <85 and PTV ≥85.

	Total (n = 44)	PTV < 85 (n = 13)	PTV ≥ 85 (n = 31)	p value
Grade ≥2 toxicity
Acute GI	7 (15.9%)	0	7 (22.6%)	.086
Acute GU	15 (34.1%)	1 (7.7%)	14 (45.2%)	.034*
Late GI	4 (9.3%)	0	4 (12.9%)	.563
Late GU	5 (11.6%)	0	5 (16.1%)	.300

PTV: planning target volume; GU: genitourinary; GI: gastrointestinal.